Kazia Therapeutics Limited (KZIA)
NASDAQ:KZIA
Want to see KZIA full AI Analyst Report?
Top Page
Kazia Therapeutics
(NASDAQ:KZIA)
Select Model
Select Model
Rating:45Neutral
Price Target:
$13.50
▲(109.63% Upside)
Action:Reiterated
Date:06/04/26
The score is held down primarily by weak financial performance (minimal and declining revenue, large ongoing losses, persistent cash burn, and negative equity). Technicals are mixed—near-term weakness with some longer-term trend support—providing only limited offset. Valuation support is also limited because the company is loss-making (negative P/E) and no dividend yield is provided.
Positive Factors
Experienced CFO hire
Adding James Levine, a veteran dealmaker with investment banking and biotech CFO experience, strengthens capital markets access, licensing and M&A capability. His track record supports durable financing and partnership execution needed to fund pivotal registrational plans and scale the oncology pipeline.
Negative Factors
Minimal, volatile revenue
A negligible and highly volatile revenue base means the business cannot self-fund development or demonstrate commercial traction. Over the medium term this forces reliance on external capital, increasing funding risk and making long-term operational planning dependent on successful clinical or partner milestones.
Read all positive and negative factors
Positive Factors
Negative Factors
Experienced CFO hire
Adding James Levine, a veteran dealmaker with investment banking and biotech CFO experience, strengthens capital markets access, licensing and M&A capability. His track record supports durable financing and partnership execution needed to fund pivotal registrational plans and scale the oncology pipeline.
Read all positive factors
Kazia Therapeutics (KZIA) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$166.53M
Dividend YieldN/A
Average Volume (3M)209.48K
Price to Earnings (P/E)―
Beta (1Y)2.21
Revenue Growth-98.25%
EPS Growth76.83%
CountryUS
Employees6
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)N/A
Shares Outstanding11,335,992
10 Day Avg. Volume60,839
30 Day Avg. Volume209,481
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)-1.26
Price to Sales (P/S)248.45
P/FCF Ratio-0.79
Enterprise Value/Market Cap-0.22
Enterprise Value/Revenue-1.85K
Enterprise Value/Gross Profit-1.85K
Enterprise Value/Ebitda2.01
Forecast
1Y Price Target
$26.25Price Target Upside307.61% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Kazia Therapeutics Business Overview & Revenue Model
Company Description
Kazia Therapeutics Limited, together with its subsidiaries, operates as an oncology-focused biotechnology company in Israel. The company's lead development candidate is paxalisib, a small molecule, brain-penetrant inhibitor of the phosphoinositide...
How the Company Makes Money
null...
Kazia Therapeutics Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
28
Negative
Cash Flow
20
Very Negative
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 19.71K | 42.00K | 2.31M | 555.00 | 10.00K | 15.18M |
| Gross Profit | 19.71K | 42.00K | 2.31M | 555.00 | 10.00K | 15.18M |
| EBITDA | -18.15M | -13.28M | -26.59M | -22.28M | -23.52M | -5.11M |
| Net Income | -22.27M | -20.70M | -26.78M | -20.47M | -25.01M | -8.42M |
Balance Sheet | ||||||
| Total Assets | 71.04M | 6.06M | 21.59M | 28.08M | 35.89M | 58.09M |
| Cash, Cash Equivalents and Short-Term Investments | 69.39M | 4.34M | 1.66M | 5.24M | 7.36M | 27.59M |
| Total Debt | 98.71K | 396.00K | 634.00K | 1.80M | 1.84M | 0.00 |
| Total Liabilities | 24.62M | 14.36M | 31.60M | 16.03M | 17.61M | 20.24M |
| Stockholders Equity | 46.42M | -8.30M | -10.02M | 12.05M | 18.27M | 37.85M |
Cash Flow | ||||||
| Free Cash Flow | -9.07M | -13.28M | -9.58M | -15.16M | -22.76M | -9.11M |
| Operating Cash Flow | -13.22M | -13.28M | -9.58M | -15.16M | -22.76M | -9.11M |
| Investing Cash Flow | 0.00 | 0.00 | 0.00 | 0.00 | -2.37M | 0.00 |
| Financing Cash Flow | 79.08M | 15.98M | 5.99M | 12.97M | 3.73M | 28.11M |
Kazia Therapeutics Technical Analysis
Positive
6.44
Price Trends
12.62
Positive
9.96
Positive
9.00
Positive
Market Momentum
0.60
Negative
63.18
Neutral
82.89
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For KZIA, the sentiment is Positive. The current price of 6.44 is below the 20-day moving average (MA) of 12.79, below the 50-day MA of 12.62, and below the 200-day MA of 9.00, indicating a bullish trend. The MACD of 0.60 indicates Negative momentum. The RSI at 63.18 is Neutral, neither overbought nor oversold. The STOCH value of 82.89 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for KZIA.
Kazia Therapeutics Risk Analysis
Kazia Therapeutics disclosed 37 risk factors in its most recent earnings report. Kazia Therapeutics reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 3 New Risks
1.
Holders of the ADSs are not treated as holders of our ordinary shares. Q2, 2024
2.
We have a history of operating losses and we expect to continue to incur losses and may never be profitable. Q2, 2024
3.
If the Company fails to comply with the rules under the Sarbanes-Oxley Act of 2002 related to accounting controls and procedures in the future, or, if the Company discovers material weaknesses and other deficiencies in our internal control and accounting procedures, the price of the ADSs could decline significantly and raising capital could be more difficult. Q2, 2024
Kazia Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $4.61M | -0.10 | -684.86% | ― | ― | 95.40% | |
46 Neutral | $12.08M | -0.71 | -107.58% | ― | ― | 77.90% | |
45 Neutral | $166.53M | -2.05 | -116.86% | ― | -98.25% | 76.83% | |
| ― | $6.33M | -4.47 | ― | ― | ― | ― | |
44 Neutral | $22.84M | -1.96 | -73.29% | ― | -43.86% | 49.21% |
* Healthcare Sector Average
KZIA
Kazia Therapeutics
14.63
8.04
122.00%
PHIO
Phio Pharmaceuticals
1.02
-1.15
-53.00%
XTLB
XTL Biopharmaceuticals Sponsored ADR
2.79
-2.01
-41.92%
MRKR
Marker Therapeutics
1.31
-0.18
-12.08%
RNAZ
TransCode Therapeutics
4.90
-2.77
-36.10%
Kazia Therapeutics Corporate Events
Kazia Therapeutics Names Veteran Dealmaker James Levine as CFO to Support Next Phase of Oncology Growth
Jun 2, 2026
Kazia Therapeutics has appointed James Levine as Chief Financial Officer, effective June 1, 2026, strengthening its executive team with more than two decades of investment banking and biotech financial leadership experience. His compensation inclu...
Kazia Therapeutics Expands Phase 1b Paxalisib Trial in Advanced Triple-Negative Breast Cancer
May 26, 2026
On May 26, 2026, Kazia Therapeutics said it will expand its ongoing Phase 1b trial of lead asset paxalisib in combination with pembrolizumab and chemotherapy for patients with advanced triple-negative breast cancer, tripling planned enrollment fro...
Kazia Therapeutics Unveils April 2026 Investor Update Showcasing Multi-Modal Oncology Pipeline
Apr 27, 2026
On April 27, 2026, Kazia Therapeutics filed a Form 6-K with the U.S. SEC, furnishing an updated corporate investor presentation and fact sheet that outline its clinical-stage oncology pipeline and strategic direction. The materials highlight a foc...
Kazia Therapeutics Names Epigenetics Pioneer Sudha Rao as Chief Scientific Officer to Drive Oncology Platform
Apr 15, 2026
On April 10, 2026, Kazia Therapeutics entered into an employment agreement with translational epigenetics expert Dr. Sudha Rao to become its Chief Scientific Officer, effective April 13, 2026, on a part-time basis. The package includes an annual s...
Kazia Therapeutics Licenses SETDB1 Epigenetic Platform to Bolster Oncology Pipeline
Apr 13, 2026
On April 10, 2026, Kazia Therapeutics entered a license and commercialization agreement with QIMR Berghofer Medical Research Institute to acquire exclusive global rights to a first-in-class SETDB1-targeted epigenetic drug development platform. The...
Kazia Therapeutics Announces Board Changes and AGM Outcomes as It Highlights Oncology Pipeline
Apr 1, 2026
On March 26, 2026, Kazia Therapeutics Limited, a Sydney-based clinical-stage oncology company focused on high-need CNS cancers and aggressive solid tumors, announced that Chairman Bryce Carmine had notified the board of his intention to retire. Hi...
Kazia Therapeutics Taps Leerink for New ATM Facility as Cash Bolstered by Late-2025 PIPE
Mar 30, 2026
Kazia Therapeutics Limited, an Australian oncology-focused RD company developing assets such as paxalisib and EVT801 and listed on Nasdaq via ADSs, reported a net loss of $12.6 million for the half year to 31 December 2025, with operating cash out...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.